Do analysts prefer PYPD or POAI?

PolyPid currently has a consensus target price of $12.25, suggesting a potential upside of 165.15%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts plainly believe PolyPid is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SKIN or POAI?

Beauty Health currently has a consensus target price of $2.02, suggesting a potential upside of 208.96%. Given Beauty Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Beauty Health is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beauty Health 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend OM or POAI?

Outset Medical presently has a consensus price target of $10.00, suggesting a potential upside of 122.72%. Given Outset Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Outset Medical is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outset Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer NRXS or POAI?

NeurAxis presently has a consensus target price of $13.00, indicating a potential upside of 94.03%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts clearly believe NeurAxis is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend POAI or ECOR?

electroCore has a consensus price target of $18.00, indicating a potential upside of 75.61%. Given electroCore's stronger consensus rating and higher probable upside, analysts clearly believe electroCore is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 electroCore 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Predictive Oncology (POAI) Competitors

$7.16 +0.54 (+8.16%)

As of 06/11/2026

Compare

POAI vs. PYPD, SKIN, OM, NRXS, and ECOR

Should you buy Predictive Oncology stock or one of its competitors? MarketBeat compares Predictive Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Predictive Oncology include PolyPid (PYPD), Beauty Health (SKIN), Outset Medical (OM), NeurAxis (NRXS), and electroCore (ECOR). These companies are all part of the "medical equipment" industry.

How does Predictive Oncology compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, PolyPid had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for PolyPid and 0 mentions for Predictive Oncology. PolyPid's average media sentiment score of 0.53 beat Predictive Oncology's score of 0.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Positive
Predictive Oncology	Neutral

Predictive Oncology has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Predictive Oncology	$1.66M	14.60	-$12.66M	-$13.50	N/A

PolyPid has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. PolyPid's return on equity of -241.96% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

PolyPid has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

26.5% of PolyPid shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PolyPid currently has a consensus target price of $12.25, suggesting a potential upside of 165.15%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts plainly believe PolyPid is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PolyPid beats Predictive Oncology on 12 of the 15 factors compared between the two stocks.

How does Predictive Oncology compare to Beauty Health?

Beauty Health (NASDAQ:SKIN) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Beauty Health has a net margin of -2.03% compared to Predictive Oncology's net margin of -5,065.23%. Beauty Health's return on equity of -9.38% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beauty Health	-2.03%	-9.38%	-1.21%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Beauty Health currently has a consensus target price of $2.02, suggesting a potential upside of 208.96%. Given Beauty Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Beauty Health is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beauty Health	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

93.3% of Beauty Health shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 40.3% of Beauty Health shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Beauty Health had 9 more articles in the media than Predictive Oncology. MarketBeat recorded 9 mentions for Beauty Health and 0 mentions for Predictive Oncology. Beauty Health's average media sentiment score of 1.15 beat Predictive Oncology's score of 0.00 indicating that Beauty Health is being referred to more favorably in the media.

Company	Overall Sentiment
Beauty Health	Positive
Predictive Oncology	Neutral

Beauty Health has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Beauty Health has higher revenue and earnings than Predictive Oncology. Beauty Health is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beauty Health	$300.80M	0.28	-$9.52M	-$0.17	N/A
Predictive Oncology	$1.66M	14.60	-$12.66M	-$13.50	N/A

Summary

Beauty Health beats Predictive Oncology on 13 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to Outset Medical?

Outset Medical (NASDAQ:OM) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Outset Medical has a net margin of -63.65% compared to Predictive Oncology's net margin of -5,065.23%. Outset Medical's return on equity of -56.13% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Outset Medical	-63.65%	-56.13%	-27.45%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Predictive Oncology has lower revenue, but higher earnings than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outset Medical	$119.48M	0.70	-$81.65M	-$4.16	N/A
Predictive Oncology	$1.66M	14.60	-$12.66M	-$13.50	N/A

In the previous week, Outset Medical had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for Outset Medical and 0 mentions for Predictive Oncology. Outset Medical's average media sentiment score of 0.35 beat Predictive Oncology's score of 0.00 indicating that Outset Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Outset Medical	Neutral
Predictive Oncology	Neutral

Outset Medical has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Outset Medical presently has a consensus price target of $10.00, suggesting a potential upside of 122.72%. Given Outset Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Outset Medical is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.0% of Predictive Oncology shares are owned by institutional investors. 2.5% of Outset Medical shares are owned by insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Outset Medical beats Predictive Oncology on 12 of the 16 factors compared between the two stocks.

How does Predictive Oncology compare to NeurAxis?

NeurAxis (NASDAQ:NRXS) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NeurAxis has a net margin of -492.76% compared to Predictive Oncology's net margin of -5,065.23%. NeurAxis' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

NeurAxis presently has a consensus target price of $13.00, indicating a potential upside of 94.03%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts clearly believe NeurAxis is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Predictive Oncology has lower revenue, but higher earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	19.38	-$14.63M	-$0.81	N/A
Predictive Oncology	$1.66M	14.60	-$12.66M	-$13.50	N/A

NeurAxis has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

In the previous week, NeurAxis had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for NeurAxis and 0 mentions for Predictive Oncology. NeurAxis' average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company	Overall Sentiment
NeurAxis	Neutral
Predictive Oncology	Neutral

Summary

NeurAxis beats Predictive Oncology on 12 of the 15 factors compared between the two stocks.

How does Predictive Oncology compare to electroCore?

Predictive Oncology (NASDAQ:POAI) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, electroCore has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, electroCore had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for electroCore and 0 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.00 beat electroCore's score of -0.04 indicating that Predictive Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Predictive Oncology	Neutral
electroCore	Neutral

electroCore has a consensus price target of $18.00, indicating a potential upside of 75.61%. Given electroCore's stronger consensus rating and higher probable upside, analysts clearly believe electroCore is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Predictive Oncology has higher earnings, but lower revenue than electroCore. electroCore is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	14.60	-$12.66M	-$13.50	N/A
electroCore	$32.03M	2.66	-$13.97M	-$1.77	N/A

electroCore has a net margin of -44.08% compared to Predictive Oncology's net margin of -5,065.23%. Predictive Oncology's return on equity of -732.73% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
electroCore	-44.08%	-1,956.38%	-83.30%

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 26.7% of electroCore shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by company insiders. Comparatively, 13.8% of electroCore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

electroCore beats Predictive Oncology on 10 of the 16 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POAI vs. The Competition

Export

Metric	Predictive Oncology	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.30M	$1.53B	$6.75B	$12.02B
Dividend Yield	N/A	N/A	2.66%	5.61%
P/E Ratio	-0.53	77.55	24.02	24.43
Price / Sales	14.60	6.96	510.75	109.73
Price / Cash	N/A	23.20	44.01	55.64
Price / Book	-15.57	4.81	10.66	6.79
Net Income	-$12.66M	-$54.76M	$3.56B	$337.66M
7 Day Performance	-7.37%	-3.26%	0.87%	2.57%
1 Month Performance	7.51%	1.40%	0.25%	2.04%
1 Year Performance	-50.28%	-6.46%	25.22%	30.28%

Predictive Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POAI Predictive Oncology	N/A	$7.16 +8.2%	N/A	-51.8%	$24.30M	$1.66M	N/A	30
PYPD PolyPid	2.6574 of 5 stars	$4.87 -3.9%	$12.25 +151.5%	+34.7%	$96.75M	N/A	N/A	80	Short Interest Increase
SKIN Beauty Health	3.1911 of 5 stars	$0.67 -5.3%	$2.02 +203.5%	-58.1%	$91.11M	$300.80M	N/A	1,030	Positive News
OM Outset Medical	2.4695 of 5 stars	$5.07 +3.3%	$10.00 +97.2%	-77.9%	$91.02M	$119.48M	N/A	520
NRXS NeurAxis	2.6206 of 5 stars	$7.01 -4.5%	$13.00 +85.4%	+191.3%	$86.81M	$4.28M	N/A	19	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:POAI) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Predictive Oncology (POAI) Competitors

POAI vs. PYPD, SKIN, OM, NRXS, and ECOR

How does Predictive Oncology compare to PolyPid?

Summary

How does Predictive Oncology compare to Beauty Health?

Summary

How does Predictive Oncology compare to Outset Medical?

Summary

How does Predictive Oncology compare to NeurAxis?

Summary

How does Predictive Oncology compare to electroCore?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Predictive Oncology (POAI) Competitors

POAI vs. PYPD, SKIN, OM, NRXS, and ECOR

How does Predictive Oncology compare to PolyPid?

Does the media prefer PYPD or POAI?

Which has better valuation & earnings, PYPD or POAI?

Is PYPD or POAI more profitable?

Which has more risk and volatility, PYPD or POAI?

Do institutionals and insiders hold more shares of PYPD or POAI?

Do analysts prefer PYPD or POAI?

Summary

How does Predictive Oncology compare to Beauty Health?

Is SKIN or POAI more profitable?

Do analysts recommend SKIN or POAI?

Do institutionals & insiders hold more shares of SKIN or POAI?

Does the media refer more to SKIN or POAI?

Which has more risk and volatility, SKIN or POAI?

Which has stronger valuation and earnings, SKIN or POAI?

Summary

How does Predictive Oncology compare to Outset Medical?

Is OM or POAI more profitable?

Which has better earnings & valuation, OM or POAI?

Does the media prefer OM or POAI?

Which has more volatility and risk, OM or POAI?

Do analysts recommend OM or POAI?

Do institutionals and insiders hold more shares of OM or POAI?

Summary

How does Predictive Oncology compare to NeurAxis?

Do insiders and institutionals believe in NRXS or POAI?

Is NRXS or POAI more profitable?

Do analysts prefer NRXS or POAI?

Which has preferable earnings & valuation, NRXS or POAI?

Which has more volatility and risk, NRXS or POAI?

Does the media favor NRXS or POAI?

Summary

How does Predictive Oncology compare to electroCore?

Which has more risk and volatility, POAI or ECOR?

Does the media favor POAI or ECOR?

Do analysts recommend POAI or ECOR?

Which has better valuation and earnings, POAI or ECOR?

Is POAI or ECOR more profitable?

Do insiders & institutionals believe in POAI or ECOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools